Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?
about
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsCellular targeting in autoimmunityProfile of atacicept and its potential in the treatment of systemic lupus erythematosusLupus nephritis: the evolving role of novel therapeuticsDrugs derived from phage display: from candidate identification to clinical practiceVNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicryRational clinical trial design for antibody mediated renal allograft injury.Matrix Producing Cells in Chronic Kidney Disease: Origin, Regulation, and Activation.Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to dateB-lymphocyte lineage cells and the respiratory system.Ten developments in the use of biologicals for systemic lupus erythematosus.Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets.Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies.Biologic agents in the treatment of glomerulonephritides.Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.Systemic lupus erythematosus biomarkers: the challenging quest.Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus.
P2860
Q26822421-8D4712C9-283E-48B3-B0E9-C2A7B4484288Q26824580-E330BD69-51EA-4807-AD15-80C8D5B6D52FQ26849719-D6CA8555-9512-4D28-B7D4-905D051698C4Q26998390-CBF175D4-98A1-4F15-BDE3-EEF6EF28E4BCQ27007101-43C42E2D-3D19-4EB1-BC08-5379205129CCQ33688370-3C00DD7E-405E-4D5B-B551-1F425782D604Q36173541-BB5F4C15-5C02-4C60-9203-F0C9DC023C86Q37364008-1DBE7CDA-92F7-4EA3-B039-917FBB8800BBQ37709763-33B6983F-B461-4695-9286-D44B7692536EQ38094250-3C8C9322-B0B6-45DB-BC63-38019EB6F5AAQ38105959-2D4C386E-563F-4A47-83C2-18DDC1D199F6Q38108851-88E0A9A5-15B2-4583-AB87-6F1687D8D338Q38203622-AA73A491-BEA8-4A8E-A130-BEE7F326C42EQ38289398-81A19E90-6F7E-4379-939F-D491EC7A952DQ38514894-9307989C-3D87-4778-8CA2-23B3EB64EA61Q38771936-1795BD5F-FFCC-464B-B458-F56A34A36E6BQ39053118-154CD387-703E-4883-803C-F1D2B65394E1Q39218839-E1D682E4-13A7-4768-ACD9-FF5CDD4504C5Q47547374-2BEAAB09-0CEC-4F94-BDFD-1E7BFA3CC839
P2860
Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biologic differences between v ...... her inhibitors in development?
@en
type
label
Biologic differences between v ...... her inhibitors in development?
@en
prefLabel
Biologic differences between v ...... her inhibitors in development?
@en
P2860
P1476
Biologic differences between v ...... her inhibitors in development?
@en
P2093
William Stohl
P2860
P2888
P304
P356
10.1007/S11926-012-0254-6
P577
2012-08-01T00:00:00Z
P6179
1013228277